Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study - Wikidata - wikimedia - TriplyDB

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

http://www.wikidata.org/entity/Q28291971

about

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Ivabradine as adjuvant treatment for chronic heart failure Ivabradine as adjuvant treatment for chronic heart failure Critical Questions about PARADIGM-HF and the Future The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients Heart Failure: Diagnosis, Management and Utilization Effectiveness of Ivabradine in Treating Stable Angina Pectoris Recent advances in treatment of heart failure Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine New Insights in the Diagnosis and Treatment of Heart Failure Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries Non-pharmacological modulation of the autonomic tone to treat heart failure Electrical vagus nerve stimulation for the treatment of chronic heart failure Heart failure and Alzheimer's disease Ivabradine, coronary artery disease, and heart failure: beyond rhythm control Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure: Who, What, Where, When, and How Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus Sacubitril/valsartan in heart failure: latest evidence and place in therapy Advances in the management of heart failure: the role of ivabradine Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm Drug therapy for heart failure in older patients-what do they want?Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials.2016 ESC and ACC/AHA/HFSA heart failure guideline update - what is new and why is it important?Potential new drug treatments for congestive heart failure.Heart Rate Reduction With Ivabradine Protects Against Left Ventricular Remodeling by Attenuating Infarct Expansion and Preserving Remote-Zone Contractile Function and Synchrony in a Mouse Model of Reperfused Myocardial Infarction [National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].Direct inhibition, but indirect sensitization of pacemaker activity to sympathetic tone by the interaction of endotoxin with HCN-channels.Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.Almanac 2011: Heart Failure. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more.Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial.Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.Structure of the SthK carboxy-terminal region reveals a gating mechanism for cyclic nucleotide-modulated ion channels Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort.Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.

P2860

Q22241786-9756F857-A72A-44C0-AF18-458D30ECCB5C Q24185982-829B7A7E-26CB-415A-8B40-03A2588B747E Q24201614-188A68B6-1AB6-46AA-922E-8DB6EAFC820E Q26741029-6CFDAB58-7441-425C-8779-6ACE5A173FC4 Q26741956-E4A410C6-0709-46AB-98B5-83EBD32A958B Q26745543-07D73991-9431-445A-8233-71C78210345F Q26750710-54ED5140-DCD1-4A3D-9B1B-4D0106CD3A23 Q26766223-4655872B-0A54-4CD5-AA30-286FF26C7E92 Q26773370-7C6B49A6-25F0-4346-8334-68FABF1AD1FA Q26774884-25CBC001-3E4F-40F0-ABEF-D71FCCCCB0AD Q26785931-DB4D4812-FB5D-479D-A3D6-C6EECA4EE449 Q26796261-CCC5FFD7-A8F0-45D6-980D-2DC19DB19BAC Q26801331-7B8D122C-F0B5-4FF5-B63B-09B8E7ADA74B Q26822899-C84D91C8-3377-4B8E-B212-7D93451643B7 Q26851442-3CB2B610-B840-43F7-99C9-61BE0A7FF454 Q26852526-D6510CCF-0185-4AF2-96E2-5ED93744E2A3 Q26865770-CDADC6A9-938A-4843-A973-C624E2826F26 Q27012929-A571B1D5-4D6F-4829-8A6E-CF9AC2E7A742 Q27026280-ECB6D9DC-53B3-4C36-9E54-10B820947355 Q28066310-EAB0263B-91BB-423B-B641-B92B19F7FB78 Q28070191-B403EDD5-C8CB-4554-9166-469FD5CA7866 Q28072418-E2335462-EFDD-44DF-93E8-30DFAEA99709 Q28077186-507CD150-3CC7-4E9A-822B-066F0B11ACA3 Q28083086-CE5F81EA-CB28-4D5E-88CF-FC4A8BBFD1B0 Q28264330-F81F3747-9ED5-4AFD-8399-9A5B7A3A0027 Q30235985-5A500A65-5A20-4A5B-A650-6FA497FB4C43 Q30245381-88469A9C-ABD3-4F33-AF96-F70A5B3DF446 Q30251531-0D7C855A-107E-4BE4-9C81-547F81F32042 Q30276924-CBE90C91-5CCC-40C4-9FE9-96863FF4BEBB Q30313892-77D74D9A-386E-410F-B46D-92D84A0C0526 Q30316590-9087D44A-E74A-42ED-B4BD-250CE91AD8CE Q30318221-75A41B32-72DB-4BD5-97B6-38ACD066499B Q30451215-C3FD1A47-BA5C-45F5-A839-45EBE04C3E59 Q30573351-044F057B-C57C-4EC2-8244-4E1DAD39C00F Q30583012-F9563DC8-3208-4E29-8CDB-92CC43E59FBD Q30585901-6BFA4A94-5CBE-4B1D-9879-EA22ECCD3DA8 Q30608315-C546E618-C68B-4645-B0B7-66355D93A917 Q30618578-01F1F5AA-D4B6-4D50-9CDF-98EDCA2C2968 Q30881762-C1DB6C6D-2901-4459-86A6-713F6CF27A12 Q31162392-7CB0146F-139B-4356-9996-0066E417C940

P2860

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

http://www.wikidata.org/entity/Q28291971

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@ast

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@en

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@nl

type

label

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@ast

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@en

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@nl

prefLabel

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@ast

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@en

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@nl

P1433

Q28291971-EF201EF9-1B5D-4876-B4F2-AF8BDCF1E702

P1476

Q28291971-14A14AC6-5DE2-4C4F-A9F9-851ACFC1843F

P2093

Q28291971-0DB70D59-9D1D-4B54-9BF7-B0D784A683C8

Q28291971-3CC01969-1267-4313-A1B9-D4B55B474960

Q28291971-527F0EE9-C15D-4B29-89A8-193B51362A47

Q28291971-CED5A97C-B87F-49A7-8436-CE58F862EF16

Q28291971-E28C5E2D-FF44-43FD-8110-CD8B394C374C

P304

Q28291971-216FA060-55D9-4548-B389-4F46D9390645

P31

Q28291971-37528375-9199-4959-A487-43B9A8E0FAEF

P3181

Q28291971-0017C262-0D2E-4CC7-BDFC-993F390FD97F

P356

Q28291971-C9B0FA42-2484-415C-BD81-7E2999A930FB

P407

Q28291971-D8F68CA5-D67E-4905-9AF3-44F53CA0D37F

P433

Q28291971-B47F1DB2-FFB1-46BE-96E3-46F7D85A6400

P478

Q28291971-83F4FD2C-1E4A-43B0-A085-DDA357278720

P50

Q28291971-2D3A81F4-24AE-435D-89AA-C70999DA2EC6

Q28291971-39EB4EA5-72DD-4BC6-B17A-7ED7E5FAE28D

Q28291971-A1561F6C-15D2-40E8-9BBD-4687A10F4433

P577

Q28291971-22AB7F85-D898-45E8-B459-6CF77C560B4C

P698

Q28291971-5B66D70E-A8F1-4ABC-B2A2-10AB661D1CC7

P921

Q28291971-B0DA692B-9988-45F8-B205-2A95A759E7DA

Q28291971-DA2A284E-1999-4256-9FD1-EA0E979954E5

P3181

P356

S0140-6736(10)61198-1

P1433

P1476

Ivabradine and outcomes in chr ...... mised placebo-controlled study

@en

P2093

Ariane Dubost-Brama

http://www.w3.org/2001/XMLSchema#string

Guy Lerebours

http://www.w3.org/2001/XMLSchema#string

Ian Ford

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Borer

http://www.w3.org/2001/XMLSchema#string

Michael Böhm

http://www.w3.org/2001/XMLSchema#string

P304

875-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1808274

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(10)61198-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9744

http://www.w3.org/2001/XMLSchema#string

P478

376

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20801500

http://www.w3.org/2001/XMLSchema#string

P921